Drugs / Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbed)
Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbed)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06344065 | Dec 2023 → May 2025 overdue | — | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbed) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06344065 ↗ |
| Modality | Vaccine | “Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbed), 0.5ml/vial, injection.” NCT06344065 ↗ |
| Route | Intramuscular | “The administration route for experimental vaccine is intramuscular injection of 0.5ml into the lateral deltoid muscle of the upper arm.” NCT06344065 ↗ |